{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:06:27Z","timestamp":1790222787991,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There are limited data on the nighttime blood pressure (BP)-lowering effect of esaxerenone and its effect on N-terminal pro b-type natriuretic peptide (NT-proBNP), a predictor of cardiovascular risk, according to different dipping patterns of nocturnal BP. This was a post hoc analysis of a multicenter, open-label, long-term phase 3 study of esaxerenone, a new highly selective mineralocorticoid receptor blocker, in patients with essential hypertension. Patients were classified by dipping pattern (extreme dippers, dippers, non-dippers, risers). Mean changes in BP, changes in dipping pattern, mean NT-proBNP levels, and percentage of patients with normal NT-proBNP levels (&lt;55\u2009pg\/mL) at baseline and Weeks 12 and 28 were evaluated. Nighttime systolic BP decreased in all dipping pattern groups at Week 28, with the riser group showing the greatest change (\u221225.5\u2009mmHg). A significant shift in dipping pattern and riser\/non-dipper pattern changes to dipper\/extreme dipper pattern were found from baseline to Week 28 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). The prevalence of the riser pattern decreased from 14.4% to 9.8%, and that of the non-dipper pattern from 44.7% to 39.2%. The decrease in NT-proBNP from baseline to Week 28 was statistically significant in risers, non-dippers, dippers, and extreme dippers (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, respectively). At baseline, the proportion of patients with NT-proBNP &lt;55\u2009pg\/mL was lowest in risers versus the other dipping pattern types, but after reductions in NT-proBNP in all groups to Week 28, these differences disappeared. Long-term administration of esaxerenone may be a useful treatment option for nocturnal hypertension, especially in patients with a riser pattern.<\/jats:p>","DOI":"10.1038\/s41440-021-00756-5","type":"journal-article","created":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T09:23:44Z","timestamp":1634289824000},"page":"97-105","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Effect of esaxerenone on nocturnal blood pressure and natriuretic peptide in different dipping phenotypes"],"prefix":"10.1038","volume":"45","author":[{"given":"Kazuomi","family":"Kario","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadayoshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Rakugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Yamakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,15]]},"reference":[{"key":"756_CR1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1586\/erc.09.35","volume":"7","author":"RH Fagard","year":"2009","unstructured":"Fagard RH. Dipping pattern of nocturnal blood pressure in patients with hypertension. Expert Rev Cardiovasc Ther. 2009;7:599\u2013605. https:\/\/doi.org\/10.1586\/erc.09.35","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"756_CR2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1161\/01.hyp.27.1.130","volume":"27","author":"K Kario","year":"1996","unstructured":"Kario K, Matsuo T, Kobayashi H, Imiya M, Matsuo M, Shimada K. Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers. Hypertension. 1996;27:130\u20135. https:\/\/doi.org\/10.1161\/01.hyp.27.1.130","journal-title":"Hypertension"},{"key":"756_CR3","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1161\/hy1001.092640","volume":"38","author":"K Kario","year":"2001","unstructured":"Kario K, Pickering TG, Matsuo T, Hoshide S, Schwartz JE, Shimada K. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension. 2001;38:852\u20137. https:\/\/doi.org\/10.1161\/hy1001.092640","journal-title":"Hypertension"},{"key":"756_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1081\/ceh-120028556","volume":"26","author":"K Kario","year":"2004","unstructured":"Kario K, Shimada K. Risers and extreme-dippers of nocturnal blood pressure in hypertension: Antihypertensive strategy for nocturnal blood pressure. Clin Exp Hypertens. 2004;26:177\u201389. https:\/\/doi.org\/10.1081\/ceh-120028556","journal-title":"Clin Exp Hypertens"},{"key":"756_CR5","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1097\/00004872-200211000-00017","volume":"20","author":"T Ohkubo","year":"2002","unstructured":"Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens. 2002;20:2183\u20139. https:\/\/doi.org\/10.1097\/00004872-200211000-00017","journal-title":"J Hypertens"},{"key":"756_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/hr.2009.172","volume":"33","author":"H Guo","year":"2010","unstructured":"Guo H, Tabara Y, Igase M, Yamamoto M, Ochi N, Kido T, et al. Abnormal nocturnal blood pressure profile is associated with mild cognitive impairment in the elderly: the J-SHIPP study. Hypertens Res. 2010;33:32\u20136. https:\/\/doi.org\/10.1038\/hr.2009.172","journal-title":"Hypertens Res"},{"key":"756_CR7","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/j.1468-1331.2007.01805.x","volume":"14","author":"A Siennicki-Lantz","year":"2007","unstructured":"Siennicki-Lantz A, Reinprecht F, Axelsson J, Elmst\u00e5hl S. Cerebral perfusion in the elderly with nocturnal blood pressure fall. Eur J Neurol. 2007;14:715\u201320. https:\/\/doi.org\/10.1111\/j.1468-1331.2007.01805.x","journal-title":"Eur J Neurol"},{"key":"756_CR8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/ajh\/hpw209","volume":"30","author":"G Amah","year":"2017","unstructured":"Amah G, Ouardani R, Pasteur-Rousseau A, Voicu S, Safar ME, Kubis N, et al. Extreme-dipper profile, increased aortic stiffness, and impaired subendocardial viability in hypertension. Am J Hypertens. 2017;30:417\u201326. https:\/\/doi.org\/10.1093\/ajh\/hpw209","journal-title":"Am J Hypertens"},{"key":"756_CR9","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.3109\/0886022x.2010.510615","volume":"32","author":"PE Drawz","year":"2010","unstructured":"Drawz PE, Rosenthal N, Babineau DC, Rahman M. Nighttime hospital blood pressure - a predictor of death, ESRD, and decline in glomerular filtration rate. Ren Fail. 2010;32:1036\u201343. https:\/\/doi.org\/10.3109\/0886022x.2010.510615","journal-title":"Ren Fail"},{"key":"756_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1161\/hypertensionaha.109.133900","volume":"57","author":"TW Hansen","year":"2011","unstructured":"Hansen TW, Li Y, Boggia J, Thijs L, Richart T, Staessen JA. Predictive role of the nighttime blood pressure. Hypertension. 2011;57:3\u201310. https:\/\/doi.org\/10.1161\/hypertensionaha.109.133900","journal-title":"Hypertension"},{"key":"756_CR11","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1161\/HYPERTENSIONAHA.121.17440","volume":"78","author":"K Kario","year":"2021","unstructured":"Kario K, Williams B. Nocturnal hypertension and heart failure: mechanisms, evidence, and new treatments. Hypertension. 2021;78:564\u201377. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.121.17440","journal-title":"Hypertension"},{"key":"756_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1161\/HYPERTENSIONAHA.120.14790","volume":"76","author":"T Fujiwara","year":"2020","unstructured":"Fujiwara T, Hoshide S, Kanegae H, Kario K. Cardiovascular event risks associated with masked nocturnal hypertension defined by home blood pressure monitoring in the J-HOP nocturnal blood pressure study. Hypertension. 2020;76:259\u201366. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.14790","journal-title":"Hypertension"},{"key":"756_CR13","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891\u2013975. https:\/\/doi.org\/10.1002\/ejhf.592","journal-title":"Eur J Heart Fail"},{"key":"756_CR14","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr., Colvin MM, et al. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70:776\u2013803. https:\/\/doi.org\/10.1016\/j.jacc.2017.04.025","journal-title":"J Am Coll Cardiol"},{"key":"756_CR15","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1253\/circj.CJ-19-0342","volume":"83","author":"H Tsutsui","year":"2019","unstructured":"Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, et al. JCS 2017\/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure\u2014digest version. Circ J. 2019;83:2084\u2013184. https:\/\/doi.org\/10.1253\/circj.CJ-19-0342","journal-title":"Circ J"},{"key":"756_CR16","doi-asserted-by":"publisher","first-page":"100553","DOI":"10.1016\/j.ijcha.2020.100553","volume":"29","author":"H Rudolf","year":"2020","unstructured":"Rudolf H, M\u00fcgge A, Trampisch HJ, Scharnagl H, M\u00e4rz W, Kara K. NT-proBNP for risk prediction of cardiovascular events and all-cause mortality: the getABI-study. Int J Cardiol Heart Vasc. 2020;29:100553. https:\/\/doi.org\/10.1016\/j.ijcha.2020.100553","journal-title":"Int J Cardiol Heart Vasc"},{"key":"756_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1620\/tjem.221.175","volume":"221","author":"S Yamanouchi","year":"2010","unstructured":"Yamanouchi S, Kudo D, Endo T, Kitano Y, Shinozawa Y. Blood N-terminal proBNP as a potential indicator of cardiac preload in patients with high volume load. Tohoku J Exp Med. 2010;221:175\u201380. https:\/\/doi.org\/10.1620\/tjem.221.175","journal-title":"Tohoku J Exp Med"},{"key":"756_CR18","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1161\/atvbaha.111.223669","volume":"31","author":"Y Doi","year":"2011","unstructured":"Doi Y, Ninomiya T, Hata J, Hirakawa Y, Mukai N, Ikeda F, et al. N-terminal pro-brain natriuretic peptide and risk of cardiovascular events in a japanese community: the Hisayama study. Arterioscler Thromb Vasc Biol. 2011;31:2997\u20133003. https:\/\/doi.org\/10.1161\/atvbaha.111.223669","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"756_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s10741-014-9443-x","volume":"19","author":"AC Don-Wauchope","year":"2014","unstructured":"Don-Wauchope AC, Santaguida PL, Oremus M, McKelvie R, Ali U, Brown JA, et al. Incremental predictive value of natriuretic peptides for prognosis in the chronic stable heart failure population: A systematic review. Heart Fail Rev. 2014;19:521\u201340. https:\/\/doi.org\/10.1007\/s10741-014-9443-x","journal-title":"Heart Fail Rev"},{"key":"756_CR20","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/jch.12321","volume":"16","author":"S Hoshide","year":"2014","unstructured":"Hoshide S, Nagai M, Yano Y, Ishikawa J, Eguchi K, Kario K. Association of high-sensitivity cardiac troponin T and N-terminal pro-brain-type natriuretic peptide with left ventricular structure: J-HOP study. J Clin Hypertens (Greenwich). 2014;16:354\u201361. https:\/\/doi.org\/10.1111\/jch.12321","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"756_CR21","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/jch.12500","volume":"17","author":"K Kario","year":"2015","unstructured":"Kario K, Hoshide S, Haimoto H, Yamagiwa K, Uchiba K, Nagasaka S, et al. Sleep blood pressure self-measured at home as a novel determinant of organ damage: Japan morning surge home blood pressure (J-HOP) study. J Clin Hypertens (Greenwich). 2015;17:340\u20138. https:\/\/doi.org\/10.1111\/jch.12500","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"756_CR22","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/s41440-021-00667-5","volume":"44","author":"S Hoshide","year":"2021","unstructured":"Hoshide S, Kanegae H, Kario K. Nighttime home blood pressure as a mediator of N-terminal pro-brain natriuretic peptide in cardiovascular events. Hypertens Res. 2021;44:1138\u201346. https:\/\/doi.org\/10.1038\/s41440-021-00667-5","journal-title":"Hypertens Res"},{"key":"756_CR23","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/s0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial. Lancet. 2015;386:2059\u201368. https:\/\/doi.org\/10.1016\/s0140-6736(15)00257-3","journal-title":"Lancet"},{"key":"756_CR24","unstructured":"Daiichi Sankyo Co., Ltd. Esaxerenone (minnebro): Japanese prescribing information; approved January 2019. https:\/\/www.Pmda.Go.Jp\/drugs\/2019\/p20190109003\/430574000_23100amx00011000_a100_1.Pdf. Accessed 3 June 2021."},{"key":"756_CR25","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/ajh\/hpaa155","volume":"34","author":"K Kario","year":"2021","unstructured":"Kario K, Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, et al. Effect of the nonsteroidal mineralocorticoid receptor blocker, esaxerenone, on nocturnal hypertension: A post hoc analysis of the ESAX-HTN study. Am J Hypertens. 2021;34:540\u201351. https:\/\/doi.org\/10.1093\/ajh\/hpaa155","journal-title":"Am J Hypertens"},{"key":"756_CR26","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/s41440-019-0314-7","volume":"42","author":"H Rakugi","year":"2019","unstructured":"Rakugi H, Ito S, Itoh H, Okuda Y, Yamakawa S. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension. Hypertens Res. 2019;42:1932\u201341. https:\/\/doi.org\/10.1038\/s41440-019-0314-7","journal-title":"Hypertens Res"},{"key":"756_CR27","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1001\/jamacardio.2017.2198","volume":"2","author":"J Butler","year":"2017","unstructured":"Butler J, Anstrom KJ, Felker GM, Givertz MM, Kalogeropoulos AP, Konstam MA, et al. Efficacy and safety of spironolactone in acute heart failure: The ATHENA-HF randomized clinical trial. JAMA Cardiol. 2017;2:950\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2017.2198","journal-title":"JAMA Cardiol"},{"key":"756_CR28","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314:884\u201394. https:\/\/doi.org\/10.1001\/jama.2015.10081","journal-title":"JAMA"},{"key":"756_CR29","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","volume":"37","author":"G Filippatos","year":"2016","unstructured":"Filippatos G, Anker SD, B\u00f6hm M, Gheorghiade M, K\u00f8ber L, Krum H, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J. 2016;37:2105\u201314. https:\/\/doi.org\/10.1093\/eurheartj\/ehw132","journal-title":"Eur Heart J"},{"key":"756_CR30","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3995\/jstroke.10301","volume":"37","author":"A Hata","year":"2015","unstructured":"Hata A, Kiyohara H. Biomarker for stroke: Hisayama Study [in Japanese]. Stroke. 2015;37:352\u20137. https:\/\/doi.org\/10.3995\/jstroke.10301","journal-title":"Stroke"},{"key":"756_CR31","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1097\/HJH.0000000000000221","volume":"32","author":"G Parati","year":"2014","unstructured":"Parati G, Stergiou G, O\u2019Brien E, Asmar R, Beilin L, Bilo G, et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32:1359\u201366. https:\/\/doi.org\/10.1097\/HJH.0000000000000221","journal-title":"J Hypertens"},{"key":"756_CR32","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481. https:\/\/doi.org\/10.1038\/s41440-019-0284-9","journal-title":"Hypertens Res"},{"key":"756_CR33","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3390\/jcm8101671","volume":"8","author":"B Krasi\u0144ska","year":"2019","unstructured":"Krasi\u0144ska B, Cofta S, Szczepaniak-Chiche\u0142 L, Rzymski P, Trafas T, Paluszkiewicz L, et al. The effects of eplerenone on the circadian blood pressure pattern and left ventricular hypertrophy in patients with obstructive sleep apnea and resistant hypertension-A randomized, controlled trial. J Clin Med. 2019;8:1671. https:\/\/doi.org\/10.3390\/jcm8101671","journal-title":"J Clin Med"},{"key":"756_CR34","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","volume":"761","author":"K Arai","year":"2015","unstructured":"Arai K, Homma T, Morikawa Y, Ubukata N, Tsuruoka H, Aoki K, et al. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Eur J Pharm. 2015;761:226\u201334. https:\/\/doi.org\/10.1016\/j.ejphar.2015.06.015","journal-title":"Eur J Pharm"},{"key":"756_CR35","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1161\/hypertensionaha.117.10238","volume":"71","author":"K Kario","year":"2018","unstructured":"Kario K, Chen CH, Park S, Park CG, Hoshide S, Cheng HM, et al. Consensus document on improving hypertension management in Asian patients, taking into account Asian characteristics. Hypertension. 2018;71:375\u201382. https:\/\/doi.org\/10.1161\/hypertensionaha.117.10238","journal-title":"Hypertension"},{"key":"756_CR36","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1111\/jch.13652","volume":"21","author":"K Kario","year":"2019","unstructured":"Kario K, Shin J, Chen CH, Buranakitjaroen P, Chia YC, Divinagracia R, et al. Expert panel consensus recommendations for ambulatory blood pressure monitoring in Asia: the HOPE asia network. J Clin Hypertens (Greenwich). 2019;21:1250\u201383. https:\/\/doi.org\/10.1111\/jch.13652","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"756_CR37","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1161\/hypertensionaha.118.10971","volume":"71","author":"K Kario","year":"2018","unstructured":"Kario K. Nocturnal hypertension: new technology and evidence. Hypertension. 2018;71:997\u20131009. https:\/\/doi.org\/10.1161\/hypertensionaha.118.10971","journal-title":"Hypertension"},{"key":"756_CR38","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1177\/2047487316683070","volume":"24","author":"PY Courand","year":"2017","unstructured":"Courand PY, Harbaoui B, B\u00e8cle C, Mouly-Bertin C, Lantelme P. Plasma NT-proBNP mirrors the deleterious cardiovascular and renal continuum in hypertension. Eur J Prev Cardiol. 2017;24:452\u20139. https:\/\/doi.org\/10.1177\/2047487316683070","journal-title":"Eur J Prev Cardiol"},{"key":"756_CR39","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1253\/circj.CJ-16-0740","volume":"81","author":"T Komori","year":"2017","unstructured":"Komori T, Eguchi K, Saito T, Hoshide S, Kario K. Riser pattern is a novel predictor of adverse events in heart failure patients with preserved ejection fraction. Circ J. 2017;81:220\u20136. https:\/\/doi.org\/10.1253\/circj.CJ-16-0740","journal-title":"Circ J"},{"key":"756_CR40","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2174\/1573402111666141217112655","volume":"10","author":"H Kai","year":"2014","unstructured":"Kai H, Kudo H, Takayama N, Yasuoka S, Aoki Y, Imaizumi T. Molecular mechanism of aggravation of hypertensive organ damages by short-term blood pressure variability. Curr Hypertens Rev. 2014;10:125\u201333. https:\/\/doi.org\/10.2174\/1573402111666141217112655","journal-title":"Curr Hypertens Rev"},{"key":"756_CR41","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1161\/circulationaha.120.049730","volume":"142","author":"K Kario","year":"2020","unstructured":"Kario K, Hoshide S, Mizuno H, Kabutoya T, Nishizawa M, Yoshida T, et al. Nighttime blood pressure phenotype and cardiovascular prognosis: practitioner-based nationwide JAMP study. Circulation. 2020;142:1810\u201320. https:\/\/doi.org\/10.1161\/circulationaha.120.049730","journal-title":"Circulation"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00756-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00756-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00756-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T07:09:32Z","timestamp":1639465772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00756-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,15]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["756"],"URL":"https:\/\/doi.org\/10.1038\/s41440-021-00756-5","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,15]]},"assertion":[{"value":"31 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Honoraria: KK, SI, HI, HR (Daiichi Sankyo Co., Ltd). Research funds: KK, SI, HI, HR (Daiichi Sankyo Co., Ltd). Employment: YO, SY (Daiichi Sankyo Co., Ltd).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}